CLINICAL RESEARCH OPPORTUNITY IN COVID-19
THE ADMINSTRATION OF TECHNEGAS™ IS NOT AN AGP
Cyclomedica is seeking innovative clinical sites interested in researching the effectiveness of V/Q SPECT/CT scan using Technegas™ in COVID-19 and/or understanding the implication of the disease long-term.
In order to qualify for the research grants, the site must be a current Technegas™ user. For more information, register below.
Technegas™ is not classified as an Aerosol Generating Procedure and, in more than 30 years of use, there have been no reported viral or other disease cross-contamination events associated with the use of the Technegas™ system.
For more information regarding the use of Ventilation/Perfusion procedures during the current pandemic, please refer to our guidance page on the COVID-19 situation
FOR MORE INFORMATION ON OUR RECENTLY LODGED NDA WITH THE USFDA CLICK HERE
- Available in 59 countries worldwide with 4 million patient studies performed to date
- Technegas™ as a diagnostic is innovative in seeking to expand its use beyond diagnosing PE
- The administration of Technegas™ is not an AGP. Read More
For more information about Technegas™ or the benefits of V/Q SPECT in comparison to CTPA in the diagnosis of Pulmonary Embolism, please refer to 2019 EANM guidelines and the 2018 CANM guidelines.
